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Abstract — The prevention of implant-associated infection, one of the leading causes of arthroplasty failure, 
remains a major challenge in orthopaedic surgery. The main strategies currently pursued are based on surface 
modifications to render implants less susceptible to bacterial colonization. The antimicrobial peptides of the 
innate immunity (AMPs) are considered a promising source of novel anti-infective agents and are receiving 
increasing attention in the field of medical devices due to their proven anti-biofilm properties. Our group has 
selected three AMPs derived from natural sequences, that are highly effective in vitro against prosthetic joint 
pathogens, also including antibiotic-resistant clinical isolates. These peptides maintain their antimicrobial 
activity under conditions relevant to the joint environment and are safe to osteoblast cells under similar 
conditions, which makes them suitable for orthopaedic applications. Current studies aimed at evaluating 
their anti-inflammatory and osteogenic potential will allow to identify the best candidate to be used for the 
development of novel AMP-based antibacterial coatings for arthroplasty implants. 
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1 BACKGROUND
Infection represents a potentially devastating complication of total joint arthroplasty, resulting in 
substantial morbidity and disability with huge economic and social costs [1]. Most infections are 
caused by Staphylococcus spp and often involve multidrug-resistant strains. Biofilm formation on the 
implant surface is almost universally associated with these infections, which poses relevant challenges 
to clinical management and urges development of effective methods to prevent bacterial colonization 
of prosthetic implants [1]. 
The antimicrobial peptides (AMPs) (Figure 1) are small protein components of the innate immune 
system produced in the phagocytic and the epithelial cells of mammals [2]. These molecules are 
considered promising alternatives to conventional antibiotics owing to a potent and broad-spectrum 
antimicrobial activity also against multi-drug resistant strains, capacity to inhibit biofilm formation and 
low propensity to induce selection of resistant mutants [3,4]. Importantly, immobilized AMPs have 
been shown to retain antimicrobial activity [5]. Additionally, some AMPs may inhibit inflammatory 
responses [6] and promote bone formation [7,8], which makes this class of compounds attractive 
candidates for orthopaedic applications.
Figure 1: Biological properties and therapeutic potential of AMPs.
2 OBJECTIVES
In the framework of the Trans2Care project, we are currently investigating the antimicrobial and host cell 
-directed activities of selected natural AMPs and in silico designed variants in the context of prosthetic 
joint infection, with the aim of identifying promising candidates for application in arthroplasty.
Our final goal, in collaboration with the Research Department of Valdoltra Orthopaedic Hospital 
(Ankaran, Slo; PP11, Trans2Care), is to exploit these peptides for the development of novel infection-
resistant coatings for arthroplasty implants. 
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3 APPROACH & METHODS
3.1  General approach 
To assess their potential for the development of infection-resistant orthopaedic biomaterials, AMPs are 
evaluated for: 
1. In vitro antimicrobial activity against prosthetic joint pathogens; 
2. Stability in biological fluids (e.g., human serum, synovial fluid); 
3. Toxicity towards osteoblast and blood cells; 
4. Anti-inflammatory activity (neutralization of proinflammatory bacterial components, i.e., 
lipopolysaccharide - LPS and lipoteichoic acid - LTA); 
5. Osteogenic potential (osteoblast proliferation and differentiation). 
3.2  Methods 
1. MIC-MBC determination, growth kinetics and anti-biofilm assays on reference S. aureus and 
S. epidermidis strains and clinical isolates from orthopaedic infections. Assays are performed both 
in standard media and under conditions relevant to the in vivo environment (i.e., in the presence of 
human serum, hyaluronic acid, synovial fluid). 
2. Liquid chromatography – mass spectrometry.
3. Hemolysis tests; LDH (lactate dehydrogenase) release and MTT assays on osteoblast (MG-63, Saos-2) 
and macrophage (RAW 264.7) cell lines.
4. Inhibition of LPS/LTA-induced NO release (Griess test) and cytokine induction (qPCR) in RAW 264.7 
cells.
5. MTT assay; ALP (alkaline phosphatase) activity assay and qPCR analysis of osteoblast differentiation 
markers in MG-63 cells.  
4 RESULTS
This study focuses on five cationic AMPs derived from natural sequences. All of these peptides display 
good in vitro activity against pathogens involved in prosthetic joint infections, including reference 
biofilm-forming S. aureus and S. epidermidis strains and clinical isolates from prosthetic joint infections. 
Their MIC values against these pathogens are comparable to those of cefazolin, the antibiotic of choice 
in perioperative prophylaxis in orthopaedic surgery. All peptides inhibit biofilm formation on abiotic 
surfaces at MIC values.
Three AMPs in particular appear to hold promise for orthopaedic applications as they are safe to 
osteoblast cells at microbicidal concentrations and maintain their antimicrobial activity also in the 
presence of hyaluronic acid and in synovial fluid.
Preliminary data indicate that the activity of the latter peptides is affected to a different extent by the 
presence of human serum. The stability of these AMPs in human serum and in synovial fluid is currently 
under investigation. Further studies aimed at evaluating their effects on osteoblast functions and on 
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macrophage inflammatory responses will allow to better define their potential for the development of 
innovative biomaterials for arthroplasty.
5 POTENTIAL NEW PRODUCTS & SERVICES
In collaboration with the Research Department of Valdoltra Hospital, the AMP with the best properties 
will be exploited to develop novel protective coatings for titanium implants. The idea is to incorporate 
the peptide into a chitosan film deposited on the titanium surface. The ultimate goal is to obtain 
infection-resistant biomaterials possibly also endowed with anti-inflammatory and osteoinductive 
properties. Such coatings may be suitable for joint prostheses and for various orthopaedic, maxillofacial 
and dental applications. 
6 CURRENT COLLABORATIONS
6.1 With other researchers 
Prof. A. Tossi (University of Trieste - LP, Trans2Care); 
Dr. F. Šulek, Prof. I. Milošev (Valdoltra Orthopaedic Hospital - PP11, Trans2Care).
6.2 With SMEs
Preliminary contacts with a company in the field of orthopaedic devices.
6.3 With hospitals
Ongoing collaborations with Valdoltra Orthopaedic Hospital (PP11, Trans2Care), with the University 
Hospital “S. Maria della Misericordia” of Udine and the Institute of Public Health Koper (Slo) for the 
supply of clinical samples, e.g., bacterial isolates, synovial fluid.
7 CONTACTS OR COLLABORATIONS NEEDED
Research groups specialized in bone and biomaterials studies: for sharing of knowledge-expertise-
facilities (e.g., animal experimental models); joint grant applications. 
Biomedical companies in the orthopaedic and biomaterials fields: for technical and/or financial 
support; joint grant applications. 
8 COMMUNICATION TOOLS
8.1  Conference contributions and presentations 
Conference contributions:
• Šulek F, Milošev I, D’Este F, Skerlavaj B. Trans2Care approach towards prevention of biofilm formation: 
antimicrobial coatings. 6th Central European Conference “Chemistry towards Biology”, Trieste (Italy), 
10-13.09.2013.
• Oro D, D’Este F, Skerlavaj B, Tossi A, Zanetti M. Towards novel strategies to prevent prosthetic joint 
infection: the potential of α-helical antimicrobial peptides. 6th Central European Conference 
“Chemistry towards Biology”, Trieste (Italy), 10-13.09.2013.
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• Šulek F, Milošev I, D’Este F, Skerlavaj B. Bio-molecular coating for orthopaedic implants with a strong 
antibacterial capability. “NanotechItaly 2013 – key enabling technologies for responsible innovation”, 
Venice-Mestre (Italy), 27-29.11.2013.
Oral presentations - the results of the present study have been presented at:
• Third Scientific Day of Valdoltra Orthopaedic Hospital (Ankaran, Slo, 30.11.2012)  
http://www.trans2care.eu/NewsData.aspx?IdNews=56&ViewType=Old&IdType=390, 
• Workshop “Orthopaedic diseases: Diagnostics, treatments and research” (Ankaran, Slo, 18.10.2013)  
http://www.trans2care.eu/NewsData.aspx?IdNews=89&ViewType=Old&IdType=390.
8.2  Additional information 
Trans2Care project:
www.trans2care.eu
University of Udine:
www.uniud.it
www.trans2care.eu/PartnerData.aspx?section=377.424&IdPartner=93
Authors: 
linkedin.com/in/francescadeste  
researchgate.net/researcher/39862473_Barbara_Skerlavaj/ 
it.linkedin.com/pub/debora-oro/77/550/317
9 FUNDS NEEDED
9.1 For basic research (investigation of biological mechanisms): 22.000€,    
 personnel costs included.
9.2 For applied research (solutions for real-world problems): 22.000€,    
 personnel costs included.
9.2 For pilot & demonstrator activities (to develop a prototype): 22.000€,    
 personnel costs included.
10 CONCLUSION
In the present study we have selected three promising AMP candidates for orthopaedic applications. 
Current efforts are aimed at incorporating one of these peptides in a chitosan antibacterial coating 
synthesized at the Valdoltra Hospital. Such functionalization of the coating may allow to enhance and 
broaden its antibacterial capability while minimising the risk of raising pathogen resistance. Moreover, 
given the proven multifunctionality of AMPs and their ability to interact with the host cells, we have 
in the pipeline the possibility to test additional properties of the AMPs under study that could be 
advantageous in the context of prosthetic joint infection.
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